Mekanistic Therapeutics, LLC

Ypsilanti, MI · Biotech · Private

Dual EGFR/PI3K kinase inhibitors for cancer, specifically MTX-531 targeting head and neck squamous cell carcinomas

Grants
$4.0M
6 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
8
1 granted · 7 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · Development of MTX-211 for the Treatment of KRAS Mutant Colorectal Cancer$275,000
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · Development of MTX for the Treatment of KRAS Mutant Colorectal Cancer$275,000
Federal grantDepartment of Health and Human Services · Phase II · Development of MTX-211 for the Treatment of KRAS Mutant Colorectal Cancer$1,861,575
Federal grantDepartment of Health and Human Services · Phase II · Development of MTX-211 for the Treatment of KRAS Mutant Colorectal Cancer$973,003
Federal grantDepartment of Health and Human Services · Phase I · Development of Novel Therapeutic Molecules for Treatment of Squamous Head and Neck Cancers$449,111
Federal grantDepartment of Health and Human Services · Phase I · Development of Novel Therapeutic Molecules for Treatment of Squamous Head and Neck Cancers$149,608
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1791Faknostics, LLC——
1792Green Growth Brands Inc.—$17M
1793PMed Holdings, LLC—$1.6M
1794Mekanistic Therapeutics, LLC——
1795SCIBAC INC.——
1796NATSAR PHARMACEUTICALS, INC.—$4.2M
1797vTv Therapeutics Holdings LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 8
  • Substituted Aminobenzyl Heteroaryl Compounds As Egfr And/or PI3K Inhibitorsgranted
  • Compounds Useful In Modulating Egfr And PI3Kapplication
  • Compounds Useful In Modulating Egfr And PI3Kapplication
  • Substituted Aminobenzyl Heteroaryl Compounds As Egfr And/or PI3K Inhibitorsapplication
  • Compounds Useful In Modulating Egfr And PI3Kapplication
  • Compounds Useful In Modulating Egfr And PI3Kapplication
  • Substituted Aminobenzyl Heteroaryl Compounds As Egfr And/or PI3K Inhibitorsapplication
  • Compounds Useful In Modulating Egfr And PI3Kapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.